Anish Patel Sells 6,667 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $18.04, for a total value of $120,272.68. Following the completion of the transaction, the chief operating officer now directly owns 316,643 shares in the company, valued at $5,712,239.72. This represents a 2.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Anish Patel also recently made the following trade(s):

• On Friday, March 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.44, for a total transaction of $142,940.48.
• On Friday, February 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.93, for a total transaction of $146,207.31.

Enliven Therapeutics Stock Up 4.4 %

Shares of NASDAQ:ELVN traded up $0.70 during trading on Wednesday, reaching $16.52. 598,017 shares of the company’s stock traded hands, compared to its average volume of 283,491. The firm has a market cap of $809.55 million, a PE ratio of -8.69 and a beta of 1.03. Enliven Therapeutics, Inc. has a fifty-two week low of $14.49 and a fifty-two week high of $30.03. The company has a 50-day simple moving average of $20.76 and a 200-day simple moving average of $23.51.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its position in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after purchasing an additional 1,114 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Enliven Therapeutics by 3,058.1% during the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock valued at $53,000 after acquiring an additional 2,630 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Enliven Therapeutics during the fourth quarter valued at approximately $97,000. BNP Paribas Financial Markets purchased a new position in shares of Enliven Therapeutics in the fourth quarter valued at approximately $112,000. Finally, ExodusPoint Capital Management LP acquired a new stake in shares of Enliven Therapeutics in the fourth quarter worth approximately $200,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. HC Wainwright lifted their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, March 21st. BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 price target for the company. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $38.75.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.